Menu

Latest Pharma Insights



‘Era Of Super Intelligence’ Comes To FDA Documents; Sponsors Can Still Say AI
To comply with an executive order, the FDA will begin using “super intelligence” instead of artificial intelligence in new documents and communications going forward, and eventually will update all forms and templates with the revised term.
Medtech Insight - November 16, 2026
FDA’s PCR Stance Could Force US-Only Packaging For OTC Personal Care, Warns PCPC
US Food and Drug Administration guidance 'effectively discourages' use of post-consumer recycled content in primary packaging for drug and combination products, the Personal Care Products Council says.
HBW Insight - November 16, 2026
Biopharma Financial Conditions On The Right Track After A Valuation Reset
Biopharma fundraising has been up in 2026, although valuations reset in recent months, perhaps cooling the financial markets to a healthier level of investment focused on high-quality companies with clinical-stage drug candidates as investors look to 2027.
In Vivo - November 16, 2026
As IPO Confidence Falters, Pharma M&A Seen As Market Driver In 2027
After a resurgence in biotech IPOs earlier this year, one postponed launch suggests confidence in the public markets is fragile.
Scrip - November 16, 2026
Jefferies 2026: Zealand CEO Trumpets Rare Disease Assets
The Danish drugmaker's future prospects are inextricably linked to its big pharma partnerships in metabolic disease. but it also has some interesting products beyond obesity.
Scrip - November 16, 2026
Biocon Gets FDA Approval For Perjeta Biosimilar, But What Is The US Market Worth?
Biocon has received FDA approval for its biosimilar to Roche/Genentech’s Perjeta and has claimed the earliest licensed launch dates for its Pebrilzo, but what is the US pertuzumab market size it could tap?
Generics Bulletin - November 16, 2026
Roche Is First To Move NLRP3 Inhibitor Into Alzheimer’s Phase II Study
The first ever clinical outcomes study in Alzheimer’s for a candidate from the novel NLRP3 inhibitor class is underway, with the goal of blocking neuroinflammation and slowing disease progression.
Scrip - November 16, 2026
Sandoz Seeks To Gain Aflibercept Foothold In US With Private-Label Deal
As it announced the launch of its Enzeevu aflibercept rival to Eylea earlier today, Sandoz said it believed its newly-revealed private-label deal for the biosimilar would “substantially expand” the product’s reach in the US, where multiple other versions of aflibercept are already available.
Generics Bulletin - November 16, 2026
Medtech Regulators Push For Whole-Lifecycle Monitoring In 2027
Regulators across the world are moving from one-time approvals to continuous lifecycle monitoring, but most medtech manufacturers lack the systems and internal alignment to keep up, said speakers at the Veeva MedTech Summit.
Medtech Insight - November 16, 2026
Hikma Invests In 3D-Printed Supplement Gummies, Plans Middle East Launch
Hikma Ventures takes a stake in Rem3dy Health, the UK firm behind the 3D-printed dietary supplement brand Nourished, alongside an exclusive MENA commercial deal.
HBW Insight - November 16, 2026
From Target Lists to Trial Readouts: What’s Next for AI in Longevity Research
From Microsoft’s agentic discovery tools to Novartis and BioAge’s decades-long cohorts, AI is speeding target identification in aging, while trial endpoints and clinical proof remain the unresolved constraints.
In Vivo - November 16, 2026
The Insight Room: Separating AI Innovation From Theater at the Point of Care
The episode discusses how to tell real innovation from theater, what is actually proprietary in a pharma-specific AI model, and how point-of-care signals turn into recommendations.
Medtech Insight - November 16, 2026
Aspen Prepares For Generic Semaglutide Launches In Upcoming Months
Aspen has won generic semaglutide approvals in Brazil and South Africa, planning launches in coming months in markets where rivals have already launched or hold approvals.
Generics Bulletin - November 16, 2026
Execs On The Move: November 9–13, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - November 16, 2026
Sofinnova Looks To Repeat Abivax Success With New Fund
The VC has closed the €725m Crossover II fund which will provide backing for approximately 15 life sciences companies, primarily in Europe, through to clinical development, global expansion and commercialization.
Scrip - November 16, 2026
Ivonescimab CRL Indicates OS Significance, Warning To Other PD-(L)1xVEGF Bispecifics
Missing the co-primary endpoint of overall survival in the Phase III HARMONi trial, Summit/Akeso’s ivonescimab has been rejected by the US FDA for approval in post-EGFR inhibitor non-squamous NSCLC.
Scrip - November 16, 2026
Scrip’s Five Must-Know Things: Rasonque’s Stellar Launch, Biotech Deal Tips, Teva’s Innovation Pivot
In this week's episode: Rasonque’s stellar launch; veterans share partnering wisdom; pessimism over Lp(a) drugs; cell therapy promise at ACR; and Teva’s innovation ambitions.
Scrip - November 16, 2026
IQ Bar Fails NAD Test For Brain, Nutrition Claims
Firm submitted irrelevant evidence to NAD for express claim “Superior brain and body nutrition” after withdrawing numerous similar claims and implied claim that its “IQ Bars are better than competing snack bars by providing noticeable improvements in cognition, physical performance and strength.”
HBW Insight - November 16, 2026

As IPO Confidence Falters, Pharma M&A Seen As Market Driver In 2027
After a resurgence in biotech IPOs earlier this year, one postponed launch suggests confidence in the public markets is fragile.
Scrip - November 16, 2026
Jefferies 2026: Zealand CEO Trumpets Rare Disease Assets
The Danish drugmaker's future prospects are inextricably linked to its big pharma partnerships in metabolic disease. but it also has some interesting products beyond obesity.
Scrip - November 16, 2026
Roche Is First To Move NLRP3 Inhibitor Into Alzheimer’s Phase II Study
The first ever clinical outcomes study in Alzheimer’s for a candidate from the novel NLRP3 inhibitor class is underway, with the goal of blocking neuroinflammation and slowing disease progression.
Scrip - November 16, 2026
Sofinnova Looks To Repeat Abivax Success With New Fund
The VC has closed the €725m Crossover II fund which will provide backing for approximately 15 life sciences companies, primarily in Europe, through to clinical development, global expansion and commercialization.
Scrip - November 16, 2026
Ivonescimab CRL Indicates OS Significance, Warning To Other PD-(L)1xVEGF Bispecifics
Missing the co-primary endpoint of overall survival in the Phase III HARMONi trial, Summit/Akeso’s ivonescimab has been rejected by the US FDA for approval in post-EGFR inhibitor non-squamous NSCLC.
Scrip - November 16, 2026
Scrip’s Five Must-Know Things: Rasonque’s Stellar Launch, Biotech Deal Tips, Teva’s Innovation Pivot
In this week's episode: Rasonque’s stellar launch; veterans share partnering wisdom; pessimism over Lp(a) drugs; cell therapy promise at ACR; and Teva’s innovation ambitions.
Scrip - November 16, 2026

‘Era Of Super Intelligence’ Comes To FDA Documents; Sponsors Can Still Say AI
To comply with an executive order, the FDA will begin using “super intelligence” instead of artificial intelligence in new documents and communications going forward, and eventually will update all forms and templates with the revised term.
Medtech Insight - November 16, 2026
Medtech Regulators Push For Whole-Lifecycle Monitoring In 2027
Regulators across the world are moving from one-time approvals to continuous lifecycle monitoring, but most medtech manufacturers lack the systems and internal alignment to keep up, said speakers at the Veeva MedTech Summit.
Medtech Insight - November 16, 2026
The Insight Room: Separating AI Innovation From Theater at the Point of Care
The episode discusses how to tell real innovation from theater, what is actually proprietary in a pharma-specific AI model, and how point-of-care signals turn into recommendations.
Medtech Insight - November 16, 2026
Execs On The Move: November 9–13, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - November 16, 2026

FDA’s PCR Stance Could Force US-Only Packaging For OTC Personal Care, Warns PCPC
US Food and Drug Administration guidance 'effectively discourages' use of post-consumer recycled content in primary packaging for drug and combination products, the Personal Care Products Council says.
HBW Insight - November 16, 2026
Hikma Invests In 3D-Printed Supplement Gummies, Plans Middle East Launch
Hikma Ventures takes a stake in Rem3dy Health, the UK firm behind the 3D-printed dietary supplement brand Nourished, alongside an exclusive MENA commercial deal.
HBW Insight - November 16, 2026
IQ Bar Fails NAD Test For Brain, Nutrition Claims
Firm submitted irrelevant evidence to NAD for express claim “Superior brain and body nutrition” after withdrawing numerous similar claims and implied claim that its “IQ Bars are better than competing snack bars by providing noticeable improvements in cognition, physical performance and strength.”
HBW Insight - November 16, 2026

Biocon Gets FDA Approval For Perjeta Biosimilar, But What Is The US Market Worth?
Biocon has received FDA approval for its biosimilar to Roche/Genentech’s Perjeta and has claimed the earliest licensed launch dates for its Pebrilzo, but what is the US pertuzumab market size it could tap?
Generics Bulletin - November 16, 2026
Sandoz Seeks To Gain Aflibercept Foothold In US With Private-Label Deal
As it announced the launch of its Enzeevu aflibercept rival to Eylea earlier today, Sandoz said it believed its newly-revealed private-label deal for the biosimilar would “substantially expand” the product’s reach in the US, where multiple other versions of aflibercept are already available.
Generics Bulletin - November 16, 2026
Aspen Prepares For Generic Semaglutide Launches In Upcoming Months
Aspen has won generic semaglutide approvals in Brazil and South Africa, planning launches in coming months in markets where rivals have already launched or hold approvals.
Generics Bulletin - November 16, 2026

Biopharma Financial Conditions On The Right Track After A Valuation Reset
Biopharma fundraising has been up in 2026, although valuations reset in recent months, perhaps cooling the financial markets to a healthier level of investment focused on high-quality companies with clinical-stage drug candidates as investors look to 2027.
In Vivo - November 16, 2026
From Target Lists to Trial Readouts: What’s Next for AI in Longevity Research
From Microsoft’s agentic discovery tools to Novartis and BioAge’s decades-long cohorts, AI is speeding target identification in aging, while trial endpoints and clinical proof remain the unresolved constraints.
In Vivo - November 16, 2026